

# PHARMACY GNIPST BULLETIN

Volume-4, Issue-3



**GURU NANAK INSTITUTE OF PHARMACEUTICAL  
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

# Contents

**01** Message from Director and Principal

**02** Recent Researches

**03** New Drug Approvals

**04** Clinical Trial News

**05** Disease Outbreak News

**06** Campus News

**07** Special Page and Game time





## MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and best wishes to all our students, faculty members, staff, alumni, and well-wishers on the joyous and vibrant occasion of Holi.

Holi, the festival of colors, symbolizes unity, happiness, and the triumph of good over evil. It brings people together, transcending differences, and fills our lives with positivity, warmth, and renewed energy.

At GNPST, we believe in nurturing not only academic excellence but also a spirit of harmony, inclusiveness, and cultural values among our students. Festivals like Holi remind us of the importance of togetherness, mutual respect, and spreading joy in our community.

On this auspicious occasion, let us celebrate with enthusiasm while upholding values of safety, respect, and environmental responsibility. May the colors of Holi inspire creativity, innovation, and a brighter outlook toward our academic and professional journeys.

Let this festival fill your lives with happiness, success, and prosperity.

Wishing you all a safe, joyful, and colorful Holi!

*Prof. (Dr.) Abhijit Sengupta*

## MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and heartfelt best wishes to our students, faculty members, staff, alumni, and valued partners on the joyous and auspicious occasion of Holi.

Holi, the festival of colors, is a celebration of joy, unity, and the triumph of positivity over negativity. It signifies renewal, harmony, and the strengthening of bonds that bring us together as a vibrant and inclusive community.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNPST), we believe that education extends beyond academics to include cultural values, social harmony, and holistic development. Since our inception in 2005, GNPST has grown into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), accredited by NAAC and NBA, and ranked 85th in NIRF 2025. Our commitment remains steadfast in nurturing responsible professionals who uphold values of integrity, collaboration, and respect.

On this festive occasion, let us reaffirm our dedication to fostering unity, positivity, and mutual respect within our academic community. May the vibrant colors of Holi inspire creativity, enthusiasm, and a renewed spirit to achieve excellence in all our endeavors.

Let us celebrate responsibly, spreading happiness while being mindful of safety and environmental sustainability.

Wishing you all a safe, joyful, and colorful Holi!

*Prof. (Dr.) Lopamudra Datta*





## RECENT RESEARCHES



**WHO's head of emergencies reaffirms support to Lebanon's health system amid escalating needs**

**MORE INFO**

[www.who.int/](http://www.who.int/)

Lebanon's health system continues to function despite the mounting pressures of conflict, displacement and repeated attacks on health care – but without urgent action and sustained international support, access to essential health services is increasingly at risk.

Dr Chikwe Ihekweazu, Executive Director of WHO's Health Emergencies Programme, has concluded a three-day visit to Lebanon, reaffirming WHO's support for the national health emergency response. "I was deeply moved by the resilience of the displaced families I met, and by the unwavering commitment of frontline workers and partners, including WHO colleagues," said Dr Ihekweazu. "Their dedication, combined with investments in preparedness, have kept the health system functioning for now, but it is unclear how long it can withstand the repeated shocks as the conflict continues."

**Conflict deepens health crisis across Middle East, WHO says**

**MORE INFO**

[www.who.int/](http://www.who.int/)

More than ten days into the latest escalation of conflict in the Middle East, health systems across the Region are coming under strain as injuries and displacement rise, attacks on health care continue, and public health risks increase.

National health authorities in Iran report more than 1300 deaths and 9000 injuries, and in Lebanon report at least 570 deaths and more than 1400 injuries. In Israel, authorities report 15 deaths and 2142 injuries. Temporary airspace restrictions have disrupted the movement of medical supplies from WHO's global logistics hub in Dubai. More than 50 emergency supply requests, intended to benefit over 1.5 million people across 25 countries, are affected, resulting in significant backlogs. Current priority shipments include supplies planned for Al Arish, Egypt, to support the Gaza response, as well as Lebanon and Afghanistan. The first shipment, containing cholera response supplies for Mozambique, is expected to depart from the hub in the coming week.

**The role of the health sector in supporting parents and their caregiving potential**

**MORE INFO**

[www.who.int/](http://www.who.int/)

Parents and caregivers play a pivotal role in shaping the health, development and well-being of children across the life course. But they cannot do it alone. All parents need some support. Supporting parents and caregivers requires a whole-of-society approach, with coordinated responses from the health, education, social services, private and other sectors.

This webinar will explore how the health sector can better support parents and caregivers — from pregnancy through childhood and adolescence — by integrating evidence-based support into routine health services, strengthening health workers' practices, and fostering coordinated care within and across sectors.

FDA

# NEW DRUG APPROVALS

Zycubo (copper histidine)  
Injection – formerly CUTX-  
101

- Date of Approval: January 12, 2026
- Company: Sentyln Therapeutics, Inc.
- Treatment for: Menkes Disease



Yuvezzi (brimonidine tartrate and carbachol) Ophthalmic Solution – formerly Brimochol PF

- Date of Approval: January 28, 2026
- Company: Tenpoint Therapeutics, Ltd.
- Treatment for: Presbyopia



Adquey (difamylast) Ointment

- Date of Approval: February 12, 2026
- Company: Acrotech Biopharma Inc.
- Treatment for: Atopic Dermatitis



Bysanti (milsaperidone)  
Tablets

- Date of Approval: February 20, 2026
- Company: Vanda Pharmaceuticals Inc.
- Treatment for: Schizophrenia, Bipolar Disorder



Loargys (pegzilarginase-nbln)  
Injection

- Date of Approval: February 23, 2026
- Company: Immedica Pharma
- Treatment for: Arginase 1 Deficiency



Yuviwel (navepegritide)  
Lyophilized Powder for Injection – formerly TransCon CNP

- Date of Approval: February 27, 2026
- Company: Ascendis Pharma A/S
- Treatment for: Achondroplasia



lootyde (icotrokinra hydrochloride) Tablets

- Date of Approval: March 17, 2026
- Company: Johnson & Johnson
- Treatment for: Plaque Psoriasis



<https://www.drugs.com/newdrugs-archive/2025.html>



# CLINICAL TRIAL NEWS



01.

## Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

South San Francisco, CA -- March 1, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, markedly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over a period of at least 96 weeks of treatment, consistent with FENhance 2 results showing a 59% reduction in ARR.

02.

## Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to Lutathera

BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA)

03.

## Valneva Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track Designation in Systemic Lupus Erythematosus (SLE)

SPRING HOUSE, Pa., (March 3, 2026) – Johnson & Johnson (NYSE: JNJ) today announced that nipocalimab<sub>a</sub> was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE), a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.

04.

## Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

South San Francisco, CA -- March 5, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 people living with overweight and obesity (mean BMI of 37 kg/m<sup>2</sup>) in a gender-balanced trial population.

05.

## Genentech Provides Update on Phase III persevErA Study of Giredestrant Plus Palbociclib in ER-Positive Advanced Breast Cancer

South San Francisco, CA -- March 8, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbociclib for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.

06.

## Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE) March 9, 2026 -- Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety.

07.

## Pfizer and Valneva Announce Lyme Disease Vaccine Candidate PF-07307405 (LB6V) Demonstrates Strong Efficacy in Phase 3 VALOR Trial

NEW YORK & LYON, France--(BUSINESS WIRE) March 23, 2026 -- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating

[MORE INFORMATION](https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html)

[https://www.drugs.com/clinical\\_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html](https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html)



# DISEASE OUTBREAK NEWS (DONS)

February 2026

## ***Mpox: recombinant virus with genomic elements of clades Ib and IIb - Global***

14 February 2026

### **Situation at a glance**

Recombination of monkeypox virus (MPXV) strains has been documented in recent months, with two cases of a recombinant strain comprising clade Ib and IIb MPXV reported. Recombination is a known natural process that can occur when two related viruses infecting the same individual exchange genetic material, producing a new virus. The first case was detected in the United Kingdom of Great Britain and Northern Ireland (hereafter “United Kingdom”), with travel history to a country in South-East Asia, and the second in India, with travel history to a country in the Arabian Peninsula. Detailed analysis of the virus genomes shows that the two individuals fell ill several weeks apart with the same recombinant strain, suggesting that there may be further cases than are currently reported. Both cases had similar clinical presentation to that observed for other clades. Neither patient experienced severe outcomes. Contact tracing for both cases in the reporting countries has been completed; no secondary cases were detected. Based on available information, the overall WHO public health risk assessment for mpox remains unchanged: the risk is assessed as moderate for men who have sex with men with new and/or multiple partners and for sex workers or others with multiple casual sexual partners, and low for the general population without specific risk factors.



**MORE INFO** <https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON595>

## ***International food safety event: Infant formula and products containing arachidonic acid oil contaminated with cereulide toxin - Multi-country***

13 March 2026


### **Situation at a glance**

Multi-country recalls of infant formula and other products have been initiated after cereulide toxin, was detected in batches of multiple internationally distributed brands. Investigations have identified arachidonic acid (ARA) oil, used as an ingredient in the implicated products, as the source of contamination. However, the full root cause analysis and complete traceability of all affected batches remains under investigation. Contaminated formulae, nutritional products, and oil mixes have been distributed to 99 countries and territories across six WHO Regions, with the first product recalls initiated on 10 December 2025. Between 1 January and 25 February 2026, 144 suspected and confirmed cases were reported across ten countries in three WHO Regions, with investigations ongoing. Based on the available information, WHO assesses the overall public health risk as moderate due to the vulnerability of the affected population (infants), the ongoing uncertainty regarding the full extent of distribution and exposure, and remaining gaps in case detection and root cause information.



**MORE INFO** <https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON596>

# CAMPUS NEWS



1. **Success Story:** The Heartiest congratulations to our students Archis Sannigrahi and Anish Paramanik (B.Pharm) on being placed as a Nutrition Officer at Nestlé. His dedication, hard work, and perseverance have truly paid off. GNIPST is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.



2. **Consumer Rights & Responsibilities Seminar:** Guru Nanak Institute of Pharmaceutical Science and Technology organized an Awareness Program on Consumer Rights & Responsibilities Seminar on Consumer Protection Act on 27th March, 2026. Quiz, Painting, & Slogan Writing Competitions were also conducted for our beloved students.



3. **Consumer Rights & Responsibilities Seminar:** The NDLI Club of GNIPST successfully organized a one-day educational visit to the National Library of India, Kolkata on 25th March 2026 for the 1st-year students of B. Pharm and M. Pharm. This enriching visit provided students with an excellent opportunity to explore one of the largest repositories of knowledge in the country. It was a truly insightful experience, enhancing their academic curiosity and appreciation for research and learning resources.

